SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001104659-18-072717
Filing Date
2018-12-13
Accepted
2018-12-13 09:00:13
Documents
2
Group Members
BPIFRANCE INVESTISSEMENT S.A.S.BPIFRANCE S.A.CAISSE DES DEPOTSEPIC BPIFRANCEFONDS INNOBIO FPCI

Document Format Files

Seq Description Document Type Size
1 SC 13D a18-41402_1sc13d.htm SC 13D 256902
2 EX-99.1 a18-41402_1ex99d1.htm EX-99.1 24567
  Complete submission text file 0001104659-18-072717.txt   283278
Mailing Address 301 NORTH MAIN STREET, SUITE 100 ANN ARBOR MI 48104
Business Address 301 NORTH MAIN STREET, SUITE 100 ANN ARBOR MI 48104 734-845-9000
Millendo Therapeutics, Inc. (Subject) CIK: 0001544227 (see all company filings)

IRS No.: 451472564 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-87213 | Film No.: 181232263
SIC: 2834 Pharmaceutical Preparations

Mailing Address 27-31 AVENUE DU GENERAL LECLERC 94710 MAISONS ALFORT CEDEX FRANCE PARIS I0 75007
Business Address 27-31 AVENUE DU GENERAL LECLERC 94710 MAISONS ALFORT CEDEX FRANCE PARIS I0 75007 33153898789
Bpifrance Participations SA (Filed by) CIK: 0001581835 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: SC 13D